REN and hypertensive disorder: In contrast, patients with BAH are usually treated with a mineralocorticoid receptor antagonist but plasma renin levels should be monitored as a therapeutic response (as well as blood pressure) because suppressed renin, independent of blood pressure control, is associated with an increased risk of cardiometabolic events and death relative to patients with essential hypertension [5].